Contraindications (C/I) for the use of LMWH at the time of prescribing

Present

11

13.75%

Absent

67

83.75%

History and initial investigation were not sufficient to detect C/I

2

2.5%

Type of C/I^¥ (N = 11)

Uncontrolled hypertension at the time of prescribing

10

90.9%

Active major bleeding

1

9.1%

Indication validity^‡

Valid

57

71.25%

Not valid

23

28.75%

Bleeding risk^◊

IMPROVE bleeding score < 7

65

81.25%

IMPROVE bleeding score ≥ 7

15

18.75%

Dose appropriateness

Appropriate

56.25%

Not appropriate

40%

Not applicable

1.25%

Not able to verify the appropriateness of the dose

2.5%

Measuring platelets at baseline

Yes

75

93.75%

No

5

6.25%

Appropriate monitoring of plateletsᶲ

Yes

31

38.75%

No

49

61.25%

Adverse drug events other than bleeding

Osteoporosis

0

0%

Heparin induced thrombocytopenia

0

0%

Possible heparin induced thrombocytopenia (HIT)

2

2.5%

Hyperkalemia

0

0%

Hypersensitivity

0

0%